Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Follow-Up Questions
Who is the CEO of Assertio Holdings Inc?
Mr. Brendan O'Grady is the Chief Executive Officer of Assertio Holdings Inc, joining the firm since 2024.
What is the price performance of ASRT stock?
The current price of ASRT is $1.02, it has increased 4.75% in the last trading day.
What are the primary business themes or industries for Assertio Holdings Inc?
Assertio Holdings Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Assertio Holdings Inc market cap?
Assertio Holdings Inc's current market cap is $98.2M
Is Assertio Holdings Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Assertio Holdings Inc, including 2 strong buy, 7 buy, 1 hold, 0 sell, and 2 strong sell
